Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539761 | 0.90 | TSHR (0.49) | ALOX15RAB9ATSHRSLC6A1SLC6A11 | |
| SCHEMBL4762703 | 0.89 | TSHR (0.42) | ALOX15RAB9ATSHRGABRA5GABRB2 | |
| SCHEMBL12994147 | 0.80 | MAPT (0.49) | TSHRGABRA5GABRB2GABRPGABRD | |
| SCHEMBL2235927 | 0.80 | MAPT (0.49) | TSHRGABRA5GABRB2GABRPGABRD | |
| SCHEMBL8224141 | 0.80 | MAPT (0.49) | TSHRGABRA5GABRB2GABRPGABRD | |
| SCHEMBL1196568 | 0.79 | ADRB2 (0.45) | RAB9ATSHRPMP22LMNAADRB2 | |
| SCHEMBL6141274 | 0.79 | ADRB2 (0.45) | RAB9ATSHRPMP22LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL3902332 | 0.79 | MAPT (0.51) | SLC6A2SLC6A4SLC6A3MAPT | |
| Hydrochloric Acid SCHEMBL30448400 | 0.79 | MAPT (0.51) | SLC6A2SLC6A4SLC6A3MAPT | |
| Hydrochloric Acid SCHEMBL29447270 | 0.79 | MAPT (0.51) | SLC6A2SLC6A4SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | ALOX15 1409/4885RAB9A 1324/4885TSHR 3984/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALOX15 3381/4885RAB9A 2346/4885TSHR 2355/4885 |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | ALOX15 1409/4885RAB9A 1324/4885TSHR 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.